Merck & Co., Inc. (NYSE:MRK) Issues Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Merck & Co., Inc. (NYSE:MRK) released its earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13, FiscalAI reports. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The business had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. During the same quarter in the prior year, the firm earned $2.13 earnings per share. The firm’s revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. updated its FY 2026 guidance to 2.660-2.760 EPS.

Here are the key takeaways from Merck & Co., Inc.’s conference call:

• Merck raised and narrowed its 2026 revenue outlook to $66.3 billion–$67.3 billion, while maintaining confidence in continued growth driven by oncology, animal health, and newer product launches.
• New and expanding products showed strong momentum, including WINREVAIR sales up 75%, WELIREG sales up 67%, and CAPVAXIVE sales up 40%; LIPFENDRA also received FDA approval as the first oral PCSK9 inhibitor.
• Pipeline de-risking accelerated, with positive Phase III results for sac-TMT in endometrial cancer and tulisokibart in ulcerative colitis, while weekly oral HIV-treatment data and multiple upcoming regulatory milestones support Merck’s projected long-term growth opportunities.
• Second-quarter reported EPS was a loss of $0.13, including a $2.31-per-share one-time charge tied to the Terns acquisition; Merck also expects U.S. KEYTRUDA growth to moderate, an OHTUVAYRE sales unwind in the third quarter, and higher inventory reserves to pressure margins.

Merck & Co., Inc. Stock Up 0.1%

Shares of MRK traded up $0.16 during trading hours on Thursday, hitting $128.49. The company had a trading volume of 2,768,924 shares, compared to its average volume of 10,765,416. The stock has a market capitalization of $317.36 billion, a price-to-earnings ratio of 102.76, a P/E/G ratio of 5.13 and a beta of 0.19. The firm has a fifty day moving average price of $123.61 and a 200-day moving average price of $118.91. Merck & Co., Inc. has a 52-week low of $77.58 and a 52-week high of $135.05. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is currently 272.00%.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck beat second-quarter earnings and revenue expectations, with sales rising 5.1% year over year to $16.61 billion. Management raised and narrowed its 2026 sales outlook, citing strength in oncology, newer product launches and pipeline progress. MRK Q2 Earnings & Sales Beat Estimates, ’26 Sales View Raised
• Positive Sentiment: Keytruda generated $8.37 billion in second-quarter sales, up 5%, while Merck’s acquisitions and partnerships are expanding its pipeline in oncology, vaccines, infectious diseases, cardiopulmonary conditions and obesity. These efforts are intended to offset the drug’s expected loss of U.S. exclusivity in 2028. Merck Is Racing Beyond Keytruda As Its Biggest Patent Cliff Nears
• Positive Sentiment: Guggenheim raised its MRK price target to $146 from $145 and reiterated a Buy rating, implying meaningful upside based on the reported reference price. Guggenheim Raises Merck Price Target
• Positive Sentiment: Investors continue to view Merck as a relatively dependable income holding. The company has raised its dividend for 15 consecutive years and offers a yield of roughly 2.6%, supporting the stock in a market focused on earnings-backed dividends. After Q2 Earnings, Is Pfizer or Merck the Smarter Dividend Play?
• Neutral Sentiment: Health Canada approved KEYTRUDA in combination with enfortumab vedotin for certain cisplatin-ineligible patients with muscle-invasive bladder cancer. The decision expands the therapy’s use, although the commercial impact is likely gradual. Health Canada Approves KEYTRUDA for Muscle-Invasive Bladder Cancer
• Negative Sentiment: Merck reported a quarterly GAAP loss, largely because of acquisition-related charges. Investors must also assess whether substantial dealmaking can produce enough non-Keytruda growth before the 2028 patent expiration.
• Negative Sentiment: MSD discontinued tulisokibart development in systemic sclerosis-associated interstitial lung disease after mixed results, highlighting clinical and pipeline execution risk even as the drug remains under evaluation in other indications. MSD Posts a Victory and Defeat for Anti-TL1A

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on MRK. Weiss Ratings cut shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. JPMorgan Chase & Co. lifted their target price on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Wall Street Zen downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. UBS Group upped their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Finally, Morgan Stanley raised their price objective on Merck & Co., Inc. from $112.00 to $113.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. Thirteen equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $134.56.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. State Street Corp lifted its position in Merck & Co., Inc. by 1.6% in the 4th quarter. State Street Corp now owns 120,040,168 shares of the company’s stock valued at $12,737,504,000 after acquiring an additional 1,859,990 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Merck & Co., Inc. by 14.8% in the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock worth $9,098,196,000 after purchasing an additional 11,156,354 shares during the last quarter. Morgan Stanley lifted its holdings in shares of Merck & Co., Inc. by 0.8% during the fourth quarter. Morgan Stanley now owns 44,946,021 shares of the company’s stock valued at $4,731,018,000 after purchasing an additional 359,486 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Merck & Co., Inc. by 6.1% during the fourth quarter. Bank of America Corp DE now owns 27,854,441 shares of the company’s stock valued at $2,931,958,000 after buying an additional 1,602,005 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in Merck & Co., Inc. by 37.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company’s stock worth $1,973,983,000 after buying an additional 5,152,069 shares in the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.